Yoshihide Asano

List of Publications by Year in Descending Order

212 papers	4,628 citations	36 h-index	59 g-index
228 ext. papers	5,440 ext. citations	3.8 avg, IF	5.64 L-index

#	Paper	IF	Citations
212	Insights Into the Preclinical Models of SSc. *Current Treatment Options in Rheumatology*, **2021**, 7, 334	1.3	
211	Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis. *International Journal of Rheumatic Diseases*, **2021**, 24, 260-267	2.3	1
210	Endothelial CCR6 expression due to FLI1 deficiency contributes to vasculopathy associated with systemic sclerosis. *Arthritis Research and Therapy*, **2021**, 23, 283	5.7	1
209	The contribution of LIGHT to the development of systemic sclerosis by modulating IL-6 and Th1 chemokine expression in dermal fibroblasts. *Journal of Investigative Dermatology*, **2021**,	4.3	1
208	Effect of Eggshell Membrane Powder Intake on the Body Function of Healthy Individuals. *Journal of Fiber Science and Technology*, **2021**, 77, 258-265	0.8	
207	Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. *Nature Communications*, **2021**, 12, 5947	17.4	3
206	Association of serum CCL20 levels with pulmonary vascular involvement and primary biliary cholangitis in patients with systemic sclerosis. *International Journal of Rheumatic Diseases*, **2021**, 24, 711-718	2.3	4
205	Rapidly progressive interstitial lung disease associated with dermatomyositis□ongitudinal course of anti-MDA5 antibody titer in two cases. *Journal of Cutaneous Immunology and Allergy*, **2021**, 4, 78-82	0.3	
204	Serum vasohibin-1 levels: A potential marker of dermal and pulmonary fibrosis in systemic sclerosis. *Experimental Dermatology*, **2021**, 30, 951-958	4	1
203	Serum levels of tissue factor pathway inhibitor: Potential association with Raynaud's phenomenon and telangiectasia in patients with systemic sclerosis. *Journal of Dermatology*, **2021**, 48, 1253-1256	1.6	1
202	Fli1 deficiency suppresses RALDH1 activity of dermal dendritic cells and related induction of regulatory T cells: a possible role in scleroderma. *Arthritis Research and Therapy*, **2021**, 23, 137	5.7	2
201	Dermatomyositis-like eruptions and fasciitis with novel compound heterozygous MEFV mutations: Newly recognized features of a variant of familial Mediterranean fever. *Journal of Dermatology*, **2021**, 48, 1453-1456	1.6	
200	Serum S100A12 levels: Possible association with skin sclerosis and interstitial lung disease in systemic sclerosis. *Experimental Dermatology*, **2021**, 30, 409-415	4	3
199	Unusual type of scleromyxedema with multiple subcutaneous nodules, IgM-□paraproteinemia, and scleroderma-like microangiopathy.. *Journal of Scleroderma and Related Disorders*, **2021**, 6, 220-224	2.3	
198	Case of aquagenic urticaria: Case report and the results of histopathological examination. *Journal of Dermatology*, **2021**, 48, 88-91	1.6	0
197	Increased Regulatory T Cells and Decreased Myeloid-Derived Suppressor Cells Induced by High CCL17 Levels May Account for Normal Incidence of Cancers among Patients with Atopic Dermatitis. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
196	A potential contribution of decreased serum galectin-10 levels to systemic inflammation and pulmonary vascular involvement in systemic sclerosis. *Experimental Dermatology*, **2021**, 30, 959-965	4	1

195	Expert-Level Distinction of Systemic Sclerosis from Hand Photographs Using Deep Convolutional Neural Networks. *Journal of Investigative Dermatology*, **2021**, 141, 2536-2539	4.3	0
194	Case of systemic sclerosis with multiple primary malignancies in whom anti-RNA polymerase III antibody was detected by immunoprecipitation. *Journal of Dermatology*, **2020**, 47, e269-e270	1.6	0
193	Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease. *Journal of Dermatology*, **2020**, 47, 796-800	1.6	2
192	Decreased serum cathepsin S levels in patients with systemic sclerosis-associated interstitial lung disease. *Journal of Dermatology*, **2020**, 47, 1027-1032	1.6	2
191	Localized scleroderma histologically characterized by liquefaction degeneration and upper dermis fibrosis: a possible association with chemotherapy. *Clinical and Experimental Dermatology*, **2020**, 45, 632-634	1.8	1
190	Wound, pressure ulcer and burn guidelines - 1: Guidelines for wounds in general, second edition. *Journal of Dermatology*, **2020**, 47, 807-833	1.6	2
189	Altered Properties of Endothelial Cells and Mesenchymal Stem Cells Underlying the Development of Scleroderma-like Vasculopathy in KLF5 ;Fli-1 Mice. *Arthritis and Rheumatology*, **2020**, 72, 2136-2146	9.5	7
188	Subacute thyroiditis in psoriasis patients treated with biologics targeting tumor necrosis factor-□ and interleukin-17A, a report of two cases. *Journal of Cutaneous Immunology and Allergy*, **2020**, 3, 33-34	0.3	2
187	Acute exacerbation of interstitial lung disease with onset of myositis in systemic sclerosis patients: a report of two cases. *Scandinavian Journal of Rheumatology*, **2020**, 49, 247-248	1.9	
186	Regulation of skin fibrosis by RALDH1-producing dermal dendritic cells via retinoic acid-mediated regulatory T cell induction: A role in scleroderma. *Journal of Dermatological Science*, **2020**, 97, 125-134	4.3	3
185	Serum delta-like 4 levels: A possible association with interstitial lung disease in systemic sclerosis. *Journal of Dermatology*, **2020**, 47, e136-e137	1.6	
184	Wound, pressure ulcer and burn guidelines - 4: Guidelines for the management of connective tissue disease/vasculitis-associated skin ulcers. *Journal of Dermatology*, **2020**, 47, 1071-1109	1.6	2
183	Wound, pressure ulcer and burn guidelines - 6: Guidelines for the management of burns, second edition. *Journal of Dermatology*, **2020**, 47, 1207-1235	1.6	2
182	Clinical significance of endothelial vasodilatory function evaluated by EndoPAT in patients with systemic sclerosis. *Journal of Dermatology*, **2020**, 47, 609-614	1.6	3
181	Localized scleroderma-like lesions induced by the K□bner phenomenon in a patient with systemic sclerosis positive for anticentromere antibody. *European Journal of Dermatology*, **2020**, 30, 431-432	0.8	1
180	The Pathogenesis and Treatment of Systemic Sclerosis □An Understanding Based on a Disease-Specific Pahological Cascade and Organ-Specific Modifying Factors □*Nishinihon Journal of Dermatology*, **2020**, 82, 75-80	0	
179	Tumoral calcinosis in systemic lupus erythematosus associated with fat necrosis. *Journal of Dermatology*, **2020**, 47, e134-e135	1.6	1
178	Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies. *Seminars in Cell and Developmental Biology*, **2020**, 101, 146-160	7.5	15

177	Fli1 deficiency induces endothelial adipsin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis. *Rheumatology*, **2020**, 59, 2005-2015	3.9	3
176	Characteristics of Japanese patients with eosinophilic fasciitis: A brief multicenter study. *Journal of Dermatology*, **2020**, 47, 1391-1394	1.6	1
175	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respiratory Medicine,the*, **2020**, 8, 963-974	35.1	112
174	The Pathogenesis of Systemic Sclerosis: An Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies. *Journal of Clinical Medicine*, **2020**, 9,	5.1	25
173	The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method. *Modern Rheumatology*, **2020**, 30, 525-531	3.3	4
172	Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies. *International Heart Journal*, **2020**, 61, 413-418	1.8	4
171	Overlapping systemic sclerosis and sarcoidosis with mutually exclusive disease activities: a case report and analysis of previous studies. *European Journal of Dermatology*, **2020**, 30, 50-52	0.8	
170	Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study. *Arthritis Research and Therapy*, **2019**, 21, 129	5.7	10
169	Systemic sclerosis: Is the epithelium a missing piece of the pathogenic puzzle?. *Journal of Dermatological Science*, **2019**, 94, 259-265	4.3	8
168	Possible association of decreased serum CXCL14 levels with digital ulcers in patients with systemic sclerosis. *Journal of Dermatology*, **2019**, 46, 584-589	1.6	3
167	Facile fabrication of PEG-coated PLGA microspheres via SPG membrane emulsification for the treatment of scleroderma by ECM degrading enzymes. *Colloids and Surfaces B: Biointerfaces*, **2019**, 179, 453-461	6	4
166	Cyclophosphamide Pulse Therapy Normalizes Vascular Abnormalities in a Mouse Model of Systemic Sclerosis Vasculopathy. *Journal of Investigative Dermatology*, **2019**, 139, 1150-1160	4.3	1
165	A potential contribution of decreased galectin-7 expression in stratified epithelia to the development of cutaneous and oesophageal manifestations in systemic sclerosis. *Experimental Dermatology*, **2019**, 28, 536-542	4	13
164	Unique correlation profile of adiponectin and retinol-binding protein 4 in patients with systemic sclerosis. *Journal of Dermatology*, **2019**, 46, 819-820	1.6	
163	A case of scleroderma en coup de sabre with ipsilateral hearing loss and aphakia. *European Journal of Dermatology*, **2019**, 29, 423-425	0.8	1
162	Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. *Journal of Dermatology*, **2019**, 46, 1006-1013	1.6	24
161	A case of concurrent psoriasis and ulcerative colitis with development of arthritis during adalimumab treatment. *European Journal of Dermatology*, **2019**, 29, 651-653	0.8	0
160	Assessment of endothelial function during the loading phase of infliximab in psoriasis: a potential predictor of its drug survival. *International Journal of Dermatology*, **2019**, 58, 54-59	1.7	2

159	Estrogen dermatitis: Case report and examination of estrogen receptor-β in the skin. *Journal of Dermatology*, **2019**, 46, 263-266	1.6	1
158	A potential contribution of trappin-2 to the development of vasculopathy in systemic sclerosis. *Journal of the European Academy of Dermatology and Venereology*, **2019**, 33, 753-760	4.6	2
157	Increased expression of aquaporin-1 in dermal fibroblasts and dermal microvascular endothelial cells possibly contributes to skin fibrosis and edema in patients with systemic sclerosis. *Journal of Dermatological Science*, **2019**, 93, 24-32	4.3	7
156	Diagnostic criteria, severity classification and guidelines of localized scleroderma. *Journal of Dermatology*, **2018**, 45, 755-780	1.6	35
155	Diagnostic criteria, severity classification and guidelines of systemic sclerosis. *Journal of Dermatology*, **2018**, 45, 633-691	1.6	16
154	Serum Soluble CD48 Levels as a Prognostic Marker in Mycosis Fungoides and Sézary Syndrome. *Journal of Investigative Dermatology*, **2018**, 138, 2286-2288	4.3	2
153	Impact of a new simplified disability scoring system for adult patients with localized scleroderma. *Journal of Dermatology*, **2018**, 45, 431-435	1.6	2
152	Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide. *Journal of Dermatology*, **2018**, 45, e140-e141	1.6	2
151	Systemic sclerosis complicated with localized scleroderma-like lesions induced by Köbner phenomenon. *Journal of Dermatological Science*, **2018**, 89, 282-289	4.3	11
150	Interleukin-25 is involved in cutaneous T-cell lymphoma progression by establishing a T helper 2-dominant microenvironment. *British Journal of Dermatology*, **2018**, 178, 1373-1382	4	12
149	A potential contribution of psoriasin to vascular and epithelial abnormalities and inflammation in systemic sclerosis. *Journal of the European Academy of Dermatology and Venereology*, **2018**, 32, 291-297	4.6	6
148	Possible pro-inflammatory role of heparin-binding epidermal growth factor-like growth factor in the active phase of systemic sclerosis. *Journal of Dermatology*, **2018**, 45, 182-188	1.6	1
147	TBX4 is involved in the super-enhancer-driven transcriptional programs underlying features specific to lung fibroblasts. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2018**, 314, L177-L191	5.8	26
146	CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis. *Experimental Dermatology* , **2018**, 27, 1030-1037	4	27
145	Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease. *Journal of Dermatology*, **2018**, 45, 1221-1224	1.6	5
144	Gastroesophageal Reflux Disease-Related Disorders of Systemic Sclerosis Based on the Analysis of 66 Patients. *Digestion*, **2018**, 98, 201-208	3.6	5
143	Serum interleukin-34 levels in patients with systemic sclerosis: Clinical association with interstitial lung disease. *Journal of Dermatology*, **2018**, 45, 1216-1220	1.6	10
142	Fli1-haploinsufficient dermal fibroblasts promote skin-localized transdifferentiation of Th2-like regulatory T cells. *Arthritis Research and Therapy*, **2018**, 20, 23	5.7	13

141	An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosis. *Scientific Reports*, **2018**, 8, 11843	4.9	24
140	Systemic sclerosis. *Journal of Dermatology*, **2018**, 45, 128-138	1.6	62
139	Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis. *Journal of Dermatology*, **2018**, 45, 881-890	1.6	21
138	What can we learn from -deficient mice, new animal models of systemic sclerosis?. *Journal of Scleroderma and Related Disorders*, **2018**, 3, 6-13	2.3	1
137	Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study. *Journal of Dermatology*, **2018**, 45, 1425-1433	1.6	15
136	Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma. *Journal of Experimental Medicine*, **2017**, 214, 1129-1151	16.6	58
135	CXCL17 Attenuates Imiquimod-Induced Psoriasis-like Skin Inflammation by Recruiting Myeloid-Derived Suppressor Cells and Regulatory T Cells. *Journal of Immunology*, **2017**, 198, 3897-3908	5.3	27
134	Serum H-ficolin levels: Clinical association with interstitial lung disease in patients with systemic sclerosis. *Journal of Dermatology*, **2017**, 44, 1168-1171	1.6	6
133	Fli1 Deficiency Induces CXCL6 Expression in Dermal Fibroblasts and Endothelial Cells, Contributing to the Development of Fibrosis and Vasculopathy in Systemic Sclerosis. *Journal of Rheumatology*, **2017**, 44, 1198-1205	4.1	15
132	Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis. *Journal of Dermatology*, **2017**, 44, 967-971	1.6	12
131	Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease. *Scandinavian Journal of Rheumatology*, **2017**, 46, 247-252	1.9	8
130	Systemic Sclerosis Dermal Fibroblasts Suppress Th1 Cytokine Production via Galectin-9 Overproduction due to Fli1 Deficiency. *Journal of Investigative Dermatology*, **2017**, 137, 1850-1859	4.3	26
129	The impact of transcription factor Fli1 deficiency on the regulation of angiogenesis. *Experimental Dermatology*, **2017**, 26, 912-918	4	16
128	A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis. *Archives of Dermatological Research*, **2017**, 309, 833-842	3.3	6
127	Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target. *Scientific Reports*, **2017** , 7, 4397	4.9	46
126	Recent advances in the treatment of skin involvement in systemic sclerosis. *Inflammation and Regeneration*, **2017**, 37, 12	10.9	4
125	Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study. *Journal of Dermatology*, **2017**, 44, 13-17	1.6	9
124	Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis. *Arthritis and Rheumatology*, **2017**, 69, 257-267	9.5	46

123	Circulating galectin-1 concentrations in systemic sclerosis: potential contribution to digital vasculopathy. *International Journal of Rheumatic Diseases*, **2016**, 19, 622-7	2.3	12
122	A potential contribution of antimicrobial peptide LL-37 to tissue fibrosis and vasculopathy in systemic sclerosis. *British Journal of Dermatology*, **2016**, 175, 1195-1203	4	32
121	The efficacy of dantrolene sodium for muscle cramps in patients with localized scleroderma. *Journal of the European Academy of Dermatology and Venereology*, **2016**, 30, e188-e189	4.6	1
120	The wound/burn guidelines - 4: Guidelines for the management of skin ulcers associated with connective tissue disease/vasculitis. *Journal of Dermatology*, **2016**, 43, 729-57	1.6	15
119	The wound/burn guidelines - 5: Guidelines for the management of lower leg ulcers/varicose veins. *Journal of Dermatology*, **2016**, 43, 853-68	1.6	5
118	A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis. *Experimental Dermatology*, **2016**, 25, 287-92	4	17
117	The first case report of fatal acute pulmonary dysfunction in a systemic sclerosis patient treated with rituximab. *Scandinavian Journal of Rheumatology*, **2016**, 45, 249-50	1.9	5
116	Tamibarotene Ameliorates Bleomycin-Induced Dermal Fibrosis by Modulating Phenotypes of Fibroblasts, Endothelial Cells, and Immune Cells. *Journal of Investigative Dermatology*, **2016**, 136, 387-398	4.3	18
115	Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells. *Annals of the Rheumatic Diseases*, **2016**, 75, 1858-65	2.4	11
114	Effect of ambrisentan on peripheral circulation in patients with systemic sclerosis. *Modern Rheumatology*, **2016**, 26, 454-7	3.3	1
113	Serum levels of interleukin-18-binding protein isoform a: Clinical association with inflammation and pulmonary hypertension in systemic sclerosis. *Journal of Dermatology*, **2016**, 43, 912-8	1.6	9
112	Decreased interleukin-21 expression in skin and blood in advanced mycosis fungoides. *Journal of Dermatology*, **2016**, 43, 819-22	1.6	4
111	The wound/burn guidelines - 6: Guidelines for the management of burns. *Journal of Dermatology*, **2016**, 43, 989-1010	1.6	25
110	Fli1 deficiency contributes to the downregulation of endothelial protein C receptor in systemic sclerosis: a possible role in prothrombotic conditions. *British Journal of Dermatology*, **2016**, 174, 338-47	4	25
109	The wound/burn guidelines - 1: Wounds in general. *Journal of Dermatology*, **2016**, 43, 357-75	1.6	3
108	The wound/burn guidelines - 3: Guidelines for the diagnosis and treatment for diabetic ulcer/gangrene. *Journal of Dermatology*, **2016**, 43, 591-619	1.6	11
107	Serum vaspin levels: A possible correlation with digital ulcers in patients with systemic sclerosis. *Journal of Dermatology*, **2015**, 42, 528-31	1.6	9
106	Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis. *Rheumatology*, **2015**, 54, 1308-16	3.9	34

105	Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis. *International Journal of Biochemistry and Cell Biology*, **2015**, 67, 86-91	5.6	28
104	Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis. *Arthritis and Rheumatology*, **2015**, 67, 254-65	9.5	49
103	Elevated serum galectin-9 levels in patients with atopic dermatitis. *Journal of Dermatology*, **2015**, 42, 723-6	1.6	11
102	Endothelin receptor blockade ameliorates vascular fragility in endothelial cell-specific Fli-1-knockout mice by increasing Fli-1 DNA binding ability. *Arthritis and Rheumatology*, **2015**, 67, 1335-44	9.5	25
101	Serum omentin levels: A possible contribution to vascular involvement in patients with systemic sclerosis. *Journal of Dermatology*, **2015**, 42, 461-6	1.6	11
100	Vasculopathy in scleroderma. *Seminars in Immunopathology*, **2015**, 37, 489-500	12	105
99	Progranulin Overproduction Due to Fli-1 Deficiency Contributes to the Resistance of Dermal Fibroblasts to Tumor Necrosis Factor in Systemic Sclerosis. *Arthritis and Rheumatology*, **2015**, 67, 3245-55	9.5	24
98	Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 15136-41	11.5	39
97	Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. *Arthritis and Rheumatology*, **2015**, 67, 517-26	9.5	67
96	Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis. *Journal of Dermatology*, **2015**, 42, 524-7	1.6	24
95	A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis. *British Journal of Dermatology*, **2015**, 173, 681-9	4	26
94	A possible contribution of endothelial CCN1 downregulation due to Fli1 deficiency to the development of digital ulcers in systemic sclerosis. *Experimental Dermatology*, **2015**, 24, 127-32	4	37
93	TLR4, rather than TLR2, regulates wound healing through TGF- and CCL5 expression. *Journal of Dermatological Science*, **2014**, 73, 117-24	4.3	64
92	Serum levels of mannose-binding lectin in systemic sclerosis: a possible contribution to the initiation of skin sclerosis in the diffuse cutaneous subtype. *European Journal of Dermatology*, **2014**, 24, 123-5	0.8	4
91	Skin barrier dysfunction and low antimicrobial peptide expression in cutaneous T-cell lymphoma. *Clinical Cancer Research*, **2014**, 20, 4339-48	12.9	22
90	Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. *Journal of Dermatology*, **2014**, 41, 418-20	1.6	19
89	Serum resistin levels: a possible correlation with pulmonary vascular involvement in patients with systemic sclerosis. *Rheumatology International*, **2014**, 34, 1165-70	3.6	20
88	Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1. *Arthritis Research and Therapy*, **2014**, 16, R86	5.7	26

87	Serum autotaxin levels correlate with pruritus in patients with atopic dermatitis. *Journal of Investigative Dermatology*, **2014**, 134, 1745-1747	4.3	17
86	The role of IL-32 in cutaneous T-cell lymphoma. *Journal of Investigative Dermatology*, **2014**, 134, 1428-1435	4.3	40
85	Clinical correlation of brachial artery flow-mediated dilation in patients with systemic sclerosis. *Modern Rheumatology*, **2014**, 24, 106-11	3.3	20
84	Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. *Nature Communications*, **2014**, 5, 5797	17.4	98
83	Histological features of localized scleroderma 'en coup de sabre': a study of 16 cases. *Journal of the European Academy of Dermatology and Venereology*, **2014**, 28, 1805-10	4.6	22
82	Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis. *Journal of Dermatology*, **2014**, 41, 746-8	1.6	5
81	Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis. *Archives of Dermatological Research*, **2014**, 306, 331-8	3.3	42
80	Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study. *PLoS ONE*, **2014**, 9, e88150	3.7	28
79	Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis. *Journal of the European Academy of Dermatology and Venereology*, **2013**, 27, 37-42	4.6	19
78	Clinical significance of serum retinol binding protein-4 levels in patients with systemic sclerosis. *Journal of the European Academy of Dermatology and Venereology*, **2013**, 27, 337-44	4.6	12
77	Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis. *Archives of Dermatological Research*, **2013**, 305, 17-23	3.3	13
76	ICAM-1 deficiency exacerbates sarcoid-like granulomatosis induced by Propionibacterium acnes through impaired IL-10 production by regulatory T cells. *American Journal of Pathology*, **2013**, 183, 1731-1739	5.8	9
75	Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis. *Rheumatology*, **2013**, 52, 790-9	3.9	34
74	A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response. *Rheumatology*, **2013**, 52, 1239-44	3.9	23
73	Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis. *Modern Rheumatology*, **2013**, 23, 323-329	3.3	19
72	Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. *Modern Rheumatology*, **2013**, 23, 1076-1084	3.3	26
71	FRI0266 Hemodynamic complications in systemic sclerosis patients with various stages of pulmonary arterial hypertension. *Annals of the Rheumatic Diseases*, **2013**, 71, 404.1-404	2.4	
70	Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis. *Modern Rheumatology*, **2013**, 23, 884-890	3.3	14

69	Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis. *Modern Rheumatology*, **2013**, 23, 323-9	3.3	11
68	Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis. *Journal of Rheumatology*, **2012**, 39, 539-44	4.1	42
67	A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis. *PLoS ONE*, **2012**, 7, e32272	3.7	31
66	Increased serum soluble CD147 levels in patients with systemic sclerosis: association with scleroderma renal crisis. *Clinical Rheumatology*, **2012**, 31, 835-9	3.9	17
65	Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. *Journal of the European Academy of Dermatology and Venereology*, **2012**, 26, 354-60	4.6	46
64	Effects of bosentan on nondigital ulcers in patients with systemic sclerosis. *British Journal of Dermatology*, **2012**, 166, 417-21	4	19
63	Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma. *Journal of Investigative Dermatology*, **2012**, 132, 1280-9	4.3	21
62	Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases. *Modern Rheumatology*, **2012**, 22, 94-99	3.3	15
61	Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity. *Modern Rheumatology*, **2012**, 22, 668-675	3.3	26
60	Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases. *Modern Rheumatology*, **2012**, 22, 598-601	3.3	9
59	A case of taxane-induced scleroderma: a different expression profile of Fli1 proteins in dermal fibroblasts and microvascular endothelial cells compared with systemic sclerosis. *British Journal of Dermatology*, **2011**, 164, 1393-5	4	9
58	Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. *Arthritis and Rheumatism*, **2011**, 63, 3575-85		60
57	Significant attenuation of macrovascular involvement by bosentan in a patient with diffuse cutaneous systemic sclerosis with multiple digital ulcers and gangrene. *Modern Rheumatology*, **2011** , 21, 548-552	3.3	13
56	The development of Th1-mediated sarcoidosis improves the clinical course of Th2-mediated atopic dermatitis. *Modern Rheumatology*, **2011**, 21, 406-409	3.3	4
55	Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5. *Journal of Virology*, **2011**, 85, 11048-57	6.6	88
54	Disseminated cutaneous and visceral Kaposi sarcoma in a patient with rheumatoid arthritis receiving corticosteroids and tacrolimus. *Modern Rheumatology*, **2011**, 21, 309-312	3.3	3
53	Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. *Archives of Dermatology*, **2011**, 147, 391-8		219
52	Altered dynamics of transforming growth factor (TGF-) receptors in scleroderma fibroblasts. *Annals of the Rheumatic Diseases*, **2011**, 70, 384-7	2.4	10

51	Significant attenuation of macrovascular involvement by bosentan in a patient with diffuse cutaneous systemic sclerosis with multiple digital ulcers and gangrene. *Modern Rheumatology*, **2011**, 21, 548-52	3.3	7
50	Future treatments in systemic sclerosis. *Journal of Dermatology*, **2010**, 37, 54-70	1.6	88
49	The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. *Journal of Dermatological Science*, **2010**, 59, 153-62	4.3	60
48	Serum TARC/CCL17 levels are increased in dermatomyositis associated with interstitial lung disease. *Journal of Dermatological Science*, **2010**, 60, 52-4	4.3	6
47	Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. *American Journal of Pathology*, **2010**, 176, 1983-98	5.8	153
46	Phosphorylation of Fli1 at threonine 312 by protein kinase C delta promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor beta. *Molecular and Cellular Biology*, **2009**, 29, 1882-94	4.8	51
45	Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. *Molecular and Cellular Biology*, **2009**, 29, 425-34	4.8	63
44	High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. *British Journal of Dermatology*, **2007**, 156, 1058-60	4	21
43	Linear connective tissue nevus. *Pediatric Dermatology*, **2007**, 24, 439-41	1.9	12
42	Clinical features of scleroderma patients with contracture of phalanges. *Clinical Rheumatology*, **2007**, 26, 1275-7	3.9	14
41	Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. *Journal of Biological Chemistry*, **2007**, 282, 34672-83	5.4	81
40	Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis. *Rheumatology*, **2006**, 45, 303-7	3.9	18
39	Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. *Rheumatology*, **2006**, 45, 157-65	3.9	43
38	Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. *American Journal of Pathology*, **2006**, 168, 499-510	5.8	143
37	Involvement of alphavbeta5 integrin in the establishment of autocrine TGF-beta signaling in dermal fibroblasts derived from localized scleroderma. *Journal of Investigative Dermatology*, **2006**, 126, 1761-9	4.3	68
36	High-dose intravenous immunoglobulin infusion in polyarteritis nodosa: report on one case and review of the literature. *Clinical Rheumatology*, **2006**, 25, 396-8	3.9	21
35	Clinical significance of serum matrix metalloproteinase-13 levels in patients with localized scleroderma. *Clinical and Experimental Rheumatology*, **2006**, 24, 394-9	2.2	6
34	Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts. *American Journal of Pathology*, **2005**, 166, 1451-63	5.8	69

33	Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. *Journal of Immunology*, **2005**, 175, 7708-18	5.3	186
32	Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. *Journal of Clinical Investigation*, **2004**, 113, 253-64	15.9	169
31	Phosphatidylinositol 3-kinase is involved in alpha2(I) collagen gene expression in normal and scleroderma fibroblasts. *Journal of Immunology*, **2004**, 172, 7123-35	5.3	75
30	A case of peplomycin-induced scleroderma. *British Journal of Dermatology*, **2004**, 150, 1213-4	4	11
29	Serum levels of tissue inhibitor of metalloproteinase-1 and 2 in patients with eosinophilic fasciitis. *British Journal of Dermatology*, **2004**, 151, 407-12	4	32
28	Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts. *American Journal of Pathology*, **2004**, 164, 1275-92	5.8	70
27	Circulating soluble CD40 ligand in patients with eosinophilic fasciitis. *Annals of the Rheumatic Diseases*, **2003**, 62, 190-1	2.4	8
26	Elevated serum levels of manganese superoxide dismutase in patients with eosinophilic fasciitis. *Clinical Rheumatology*, **2003**, 22, 505	3.9	2
25	The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis. *Journal of Investigative Dermatology*, **2003**, 120, 204-10	4.3	26
24	Plasma plasmin-alpha2-plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension. *British Journal of Rheumatology*, **2003**, 42, 240-3		22
23	Anti-U1RNP antibodies in patients with localized scieroderma. *Archives of Dermatological Research*, **2001**, 293, 455-9	3.3	8
22	Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. *Arthritis and Rheumatism*, **2001**, 44, 1363-9		78
21	Effect of interleukin 10 on the hematopoietic progenitor cells from patients with aplastic anemia. *Stem Cells*, **1999**, 17, 147-51	5.8	9
20	Action of interleukin-3 on the proliferation of leukaemic progenitor cells from patients with acute myeloblastic leukaemia. *International Journal of Laboratory Hematology*, **1998**, 20, 225-9		1
19	Effect of (-)-epigallocatechin gallate on leukemic blast cells from patients with acute myeloblastic leukemia. *Life Sciences*, **1997**, 60, 135-42	6.8	41
18	Interleukin-10 inhibits the autocrine growth of leukemic blast cells from patients with acute myeloblastic leukemia. *International Journal of Hematology*, **1997**, 66, 445-50	2.3	9
17	Effect of the chimeric soluble granulocyte colony-stimulating factor receptor on the proliferation of leukemic blast cells from patients with acute myeloblastic leukemia. *Cancer Research*, **1997**, 57, 3395-7	10.1	7
16	Diagnosis of right ventricular overload by body surface QRST isointegral maps in children with postoperative right bundle branch block. *Journal of Electrocardiology*, **1995**, 28, 209-21	1.4	6

15	Simultaneous occurrence of human herpesvirus 6 infection and intussusception in three infants. *Pediatric Infectious Disease Journal*, **1991**, 10, 335-7	3.4	5
14	Age-related degeneracy of T cell repertoire: influence of the aged environment on T cell allorecognition. *Gerontology*, **1990**, 36 Suppl 1, 3-9	5.5	18
13	Synergistic T-T cell interaction present in alloreactivity: determination of 'MLR helper' T cell subsets. *International Immunology*, **1990**, 2, 1203-11	4.9	5
12	Drug sensitivity test for acute myeloblastic leukemia by an efficient leukemic blast colony assay using 5637-conditioned medium as a stimulator. *Journal of Medicine*, **1990**, 21, 289-99		
11	Development of drug resistance in cultured clonogenic leukemic blast cells during the clinical course of myeloblastic leukemia. *Oncology*, **1989**, 46, 339-42	3.6	5
10	Generation of T cell repertoire. Two distinct mechanisms for generation of T suppressor cells, T helper cells, and T augmenting cells. *Journal of Immunology*, **1989**, 142, 365-73	5.3	10
9	Cell membrane molecule I-J transduces a negative signal for early T-cell activation induced via the TCR. *Cold Spring Harbor Symposia on Quantitative Biology*, **1989**, 54 Pt 2, 683-8	3.9	1
8	Effect of human G-CSF on clonogenic cells in acute myeloblastic leukemia. *European Journal of Cancer & Clinical Oncology*, **1988**, 24, 1285-7		2
7	Growth of clonogenic myeloblastic leukemic cells in the presence of human recombinant erythropoietin in addition to various human recombinant hematopoietic growth factors. *Blood*, **1988**, 72, 1682-1686	2.2	45
6	Analysis of two distinct B cell activation pathways mediated by a monoclonal T helper cell. II. T helper cell secretion of interleukin 4 selectively inhibits antigen-specific B cell activation by cognate, but not noncognate, interactions with T cells. *Journal of Immunology*, **1988**, 140, 419-26	5.3	19
5	Growth of clonogenic myeloblastic leukemic cells in the presence of human recombinant erythropoietin in addition to various human recombinant hematopoietic growth factors. *Blood*, **1988**, 72, 1682-6	2.2	5
4	Growth of clonogenic myeloblastic leukemic cells in the presence of human recombinant erythropoietin in addition to various human recombinant hematopoietic growth factors. *Blood*, **1988**, 72, 1682-1686	2.2	
3	Epitopes associated with MHC restriction site of T cells. III. I-J epitope on MHC-restricted T helper cells. *Journal of Experimental Medicine*, **1987**, 166, 1613-26	16.6	13
2	Synergism of leukemic blast growth factors in medium conditioned by human bladder carcinoma cell line 5637. *International Journal of Cell Cloning*, **1987**, 5, 504-10		4
1	Effect of human recombinant granulocyte/macrophage colony-stimulating factor and native granulocyte colony-stimulating factor on clonogenic leukemic blast cells. *Cancer Research*, **1987**, 47, 5647-8	10.1	25